TTY Biopharm Company Limited (TPEX:4105)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
75.80
+0.10 (0.13%)
Jul 30, 2026, 9:55 AM CST

TTY Biopharm Company Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6,5156,4535,8945,5065,0624,536
Revenue Growth
7.16%9.49%7.05%8.77%11.60%7.43%
Gross Profit
3,7483,7213,4153,2873,0212,768
Operating Income
1,7811,7041,3941,3721,2281,141
Net Income
1,6111,5591,4501,1291,094831.89
Earnings Per Share
6.476.265.824.534.403.34
EPS Growth
3.36%7.56%28.48%2.96%31.74%-9.97%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Export and OEM Business Unit
1,2571,2491,024796.7653.68-
Healthcare Unit
267.26263.43262.41195.63581.66221.48
Re-investment Business Unit
1,4281,4281,236814.45747.28-
Intensive Care Business Unit
1,4751,4981,3171,203899.621,136
Adjustments and Eliminations
-478.35-512.98-444.41--268.62-274.72
Oncology Business Unit
2,5442,5052,4642,4302,3412,769
Other Business Unit
-21.9235.2365.44106.64270.72
Total
6,5156,4535,8945,5065,0624,536

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,3072,9893,0822,8172,6842,595
Total Debt
1,0151,2161,7111,8591,8052,145
Net Cash (Debt)
2,2921,7731,371957.65878.78450
Net Cash Growth
33.05%29.36%43.11%8.97%95.28%6.52%
Net Cash Per Share
9.207.115.503.843.531.81

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
2,0191,7621,3491,0851,2361,256
Capital Expenditures
-112.98-94.61-125.16-78.35-91.52-60.32
Free Cash Flow
1,9061,6671,2241,0071,1441,196
Free Cash Flow Growth
48.35%36.19%21.57%-12.00%-4.33%233.86%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
57.54%57.66%57.94%59.70%59.69%61.03%
Operating Margin
27.34%26.41%23.65%24.93%24.26%25.15%
Pretax Margin
33.51%32.93%31.99%25.78%27.82%23.97%
Profit Margin
24.73%24.16%24.60%20.50%21.62%18.34%
FCF Margin
29.26%25.84%20.77%18.29%22.61%26.37%

Dividends

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Dividend Per Share
4.5004.5004.2003.5003.4003.000
Dividend Per Share Growth
7.14%7.14%20.00%2.94%13.33%-25.00%
Dividend Yield
5.89%5.85%6.46%5.09%4.98%5.56%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
11.7013.0012.4917.7218.9520.56
Forward PE
-13.7416.1814.8117.4516.54
P/FCF Ratio
9.8712.1614.7919.8518.1214.30
PS Ratio
2.893.143.073.634.103.77